<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242021000102795</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Supervivencia de pacientes con cáncer de pulmón de células no pequeñas en estadios avanzados. Matanzas]]></article-title>
<article-title xml:lang="en"><![CDATA[Survival of patients with non-small cells lung cancer in advanced stages. Matanzas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camacho Sosa]]></surname>
<given-names><![CDATA[Kirenia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alonso Lemus]]></surname>
<given-names><![CDATA[Lisandry]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez Rodríguez]]></surname>
<given-names><![CDATA[Doralys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carreño Rolando]]></surname>
<given-names><![CDATA[Ihosvannys E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza Jorge]]></surname>
<given-names><![CDATA[Erasmo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Soto]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Clínico Quirúrgico Comandante &#8220;Faustino Pérez Hernández  ]]></institution>
<addr-line><![CDATA[ Matanzas]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<volume>43</volume>
<numero>1</numero>
<fpage>2795</fpage>
<lpage>2807</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242021000102795&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242021000102795&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242021000102795&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: el cáncer de pulmón de células no pequeñas en estadios avanzados tiene una alta incidencia y mortalidad. Los tratamientos que se emplean son la quimioterapia, la radioterapia, las terapias dirigidas y la inmunoterapia. Es preferible que los tratamientos se realicen en el marco de ensayos clínicos. Tiene una precaria supervivencia a los cinco años del diagnóstico.  Objetivo: determinar la supervivencia global de los pacientes con cáncer de pulmón de células no pequeñas, en estadios avanzados.  Materiales y métodos: estudio descriptivo, retrospectivo en pacientes con diagnóstico cito-histológico de cáncer de pulmón de células no pequeñas, en estadios avanzados. De un universo de 463 pacientes atendidos en el Servicio de Oncología Provincial de Matanzas, se conformó una muestra de 348. Período comprendido desde enero del 2013 a diciembre del 2016. Las variables estudiadas se tomaron de las historias clínicas y la base de datos nacional de fallecidos por cáncer de pulmón.  Resultados: la mayoría de los pacientes se diagnosticaron en etapa IV (71,69 %), la modalidad de tratamiento más utilizada fue la quimioterapia (61,2 %). Los fármacos más empleados fueron las sales de platino en el78,73 %. La supervivencia global en la etapa IV fue de 1,23 % a cinco años. La modalidad de tratamiento de mayor supervivencia fue la inmunoterapia, con 3,33 % y la supervivencia global fue de 2 %.  Conclusiones:  predominó la etapa IV de la enfermedad. La quimioterapia a base de sales de platino como esquema de tratamiento de primera línea y la inmunoterapia como modalidad de tratamiento reportaron mayor supervivencia global, aunque esta fue precaria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  non-small cell lung cancer in advanced stages shows a high incidence and mortality. The treatments used against it are chemotherapy, radiotherapy, directed therapies and immunotherapy. It is better to perform the treatments in the context of clinical trials. It has a precarious survival at the fifth year after diagnosis.  Objective:  to determine the global survival of patients with non-small cell lung cancer in advanced stages.  Materials and methods:  descriptive, retrospective study in patients with cyto-histological diagnosis of non-small lung cancer in advanced stages. A sample of 348 patients was formed from the universe of 463 patients who attended the Provincial Service of Oncology in the period from January 2013 to December 2016. The studied variables were taken from the clinical records and the national database of deceased due to lung cancer.  Results:  most of patients were diagnosed at the stage IV (71.69 %); the most used treatment modality was chemotherapy (61.2). The most used drugs were platinum salts in 78.73 %. The global survival at the IV stage was 1.23 at five years. The treatment modality of greater survival was immunotherapy, with 3.33 % and the global survival was 2 %.  Conclusions:  the disease&#8217;s stage IV predominated. The platinum salts-based chemotherapy as the first line treatment scheme and immunotherapy as treatment modality provided higher global survival, although it was precarious.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer de pulmón]]></kwd>
<kwd lng="es"><![CDATA[estadios]]></kwd>
<kwd lng="es"><![CDATA[modalidad de tratamiento]]></kwd>
<kwd lng="es"><![CDATA[supervivencia]]></kwd>
<kwd lng="en"><![CDATA[lung cancer]]></kwd>
<kwd lng="en"><![CDATA[stages]]></kwd>
<kwd lng="en"><![CDATA[treatment modality]]></kwd>
<kwd lng="en"><![CDATA[survival]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Oncology.Pro</collab>
<source><![CDATA[Thoracic Tumours: Essentials for Clinicians]]></source>
<year>2019</year>
<publisher-loc><![CDATA[EE UU ]]></publisher-loc>
<publisher-name><![CDATA[European Society for Medical Oncology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública de Cuba</collab>
<source><![CDATA[Anuario Estadístico 2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldstraw]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chansky]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Crowley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer]]></article-title>
<source><![CDATA[J Thorac Oncol]]></source>
<year>2016</year>
<volume>11</volume>
<page-range>39-51</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>American Cancer Society</collab>
<source><![CDATA[Cáncer de pulmón no microcítico]]></source>
<year>2018</year>
<publisher-loc><![CDATA[EE UU ]]></publisher-loc>
<publisher-name><![CDATA[American Cancer Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Planchard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Popat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastatic non-small Cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2018</year>
<volume>29</volume>
<numero>^ssuppl 4</numero>
<issue>^ssuppl 4</issue>
<supplement>suppl 4</supplement>
<page-range>iv192-237</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mok]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Y-L]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[M-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<page-range>629-40</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haanen]]></surname>
<given-names><![CDATA[JBAG]]></given-names>
</name>
<name>
<surname><![CDATA[Lugowska]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Garassino]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[ESMO Handbook of Immuno-Oncology]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Lugano ]]></publisher-loc>
<publisher-name><![CDATA[ESMO Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Abreu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>1823-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cobián Caballero]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta Brooks]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez FeriaII]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim Romero García]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2016</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>320</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Popa]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2016</year>
<volume>22</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>3782-90</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gastón]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad del Racotumomab en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas]]></article-title>
<source><![CDATA[VacciMonitor]]></source>
<year>2015</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-4</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neninger]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Santiesteban]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of racotumomab or nimotuzumab vs docetaxel as secondline therapy for advanced non-small cell lung cancer patients]]></article-title>
<source><![CDATA[Oncology Pro]]></source>
<year>2018</year>
<volume>29</volume>
<numero>^sSup 8</numero>
<issue>^sSup 8</issue>
<supplement>Sup 8</supplement>
<page-range>viii415</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Barcala]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Falagan]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[García-Prim]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de pulmón en el área sanitaria de Pontevedra: incidencia, presentación clínica y supervivencia]]></article-title>
<source><![CDATA[An Sist Sanit Navar]]></source>
<year>2013</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>217-27</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz Toledo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cayón Escobar]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo Díaz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia en cáncer de pulmón avanzado en pacientes mayores de 60 años de edad del Hospital Benéfico-Jurídico (2008-2011)]]></article-title>
<source><![CDATA[Rev Habanera de Ciencias Médicas]]></source>
<year>2014</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>227-37</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Vita VT]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer: Principles and Practice of Oncology]]></source>
<year>2019</year>
<edition>11th</edition>
<publisher-loc><![CDATA[Philadelphia, Pa ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams &amp; Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>NCCN</collab>
<source><![CDATA[Clinical Practice Guidelines in Oncology. Lung Cancer]]></source>
<year>2019</year>
<publisher-loc><![CDATA[EE UU ]]></publisher-loc>
<publisher-name><![CDATA[NCCN]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rafiemanesh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mehtarpour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología, incidencia y mortalidad del cáncer de pulmón y su relación con el índice de desarrollo en el mundo]]></article-title>
<source><![CDATA[J Thorac Dis]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Comisión clínica de cáncer de pulmón</collab>
<source><![CDATA[Protocolo cáncer de pulmón. Diagnóstico, tratamiento y seguimiento]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Córdoba ]]></publisher-loc>
<publisher-name><![CDATA[Servicio Andaluz de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal Perez]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia del cáncer de pulmón pacientes tratados en un hospital de referencia en Zaragoza, España]]></article-title>
<source><![CDATA[Science direct]]></source>
<year>2016</year>
<volume>42</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>380-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lage]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapias con inhibidores del receptor del factor de crecimiento epidérmico: acercando el futuro]]></article-title>
<source><![CDATA[Biotecnología Aplicada]]></source>
<year>2007</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
